Yunnan Cancer Hospital, Kunming, Yunnan 650118
Kunming, Yunnan, China
Location status: Recruiting
NCT Number: NCT07154563
Breast malignant tumors are a serious threat to women's health, and the current treatment for breast malignant tumors is still dominated by surgery, but the problems faced by patients after surgery such as edema and tumor recurrence are still relatively common, and the high recurrence rate and the occurrence of postoperative complications are closely related to the removal of metastatic lymph nodes during surgery. Therefore, accurate assessment of sentinel lymph node (SLN) metastases is essential to determine the extent of axillary lymph node dissection (ALND) and minimize complications. In this study, we developed a new technique that can rapidly distinguish between metastatic lymph nodes and normal sentinel lymph nodes (SLNs) in breast cancer patients. Briefly, fresh tissue is incubated with the probe and imaged immediately after intraoperative sentinel lymph node resection to identify the metastatic status of SLN. The accuracy of fluorescence imaging is confirmed by pathological diagnosis.
Interested in participating?
Request Info18 year–75 year
Female
Observational
Kunming, Yunnan, China
Location status: Recruiting
Following patient enrollment, surgical interventions were performed in accordance with standardized clinical protocols. During the operative procedure, the excised sentinel lymph nodes (SLNs) underwent specialized incubation processing. The detailed experimental protocol was conducted as follows:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
After incubating the lymph node tissue with an optimal concentration of NIR-II probe for an appropriate amount of time, the tissue is washed with eluent, and then the fluorescence intensity of different tissues is detected to assess whether the tissue has cancer tissue invasion.
Time frame: 1 year
Ability of the imaging system to discern the uptake of the dye by the metastatic SLN . Detected with imaging probe.
Time frame: 1 year
Microscopic examination and immunohistochemistry of tumor performed by a pathologist. This will allow investigators to compare pathology results with fluorescence images taken by imaging probe to calculate false positive (i.e., identification of non metastatic SLN) rates of ICG-CK.
Contact information is provided by the study sponsor or research team.
Junhong Chen, Postgraduate
CONTACT
86+17782287838
Weiling Chen, Doctor
CONTACT
86+13646039812
Yunnan Cancer Hospital
Other
Acronym: NIR-II
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07635147
Advanced Breast Cancer, Behavior
Brooklyn, New York, United States
View Trial DetailsNCT06072612
Breast Cancer, Breast Cancer Metastatic
Phoenix, Arizona, United States
View Trial DetailsNCT05735080
Adnexal Diseases, Advanced Cancer
Orlando, Florida, United States
View Trial DetailsNCT04150042
Adenocarcinoma of the Breast, BRCA1 Mutation
Boston, Massachusetts, United States
View Trial Details